[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.120.181. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 894
Citations 0
News From the Food and Drug Administration
February 16, 2016

New Option for Gout

JAMA. 2016;315(7):648. doi:10.1001/jama.2016.0622

Lesinurad has received FDA approval to help decrease high uric acid levels in the blood that lead to gout, a painful form of arthritis.

“Controlling hyperuricemia is critical to the long-term treatment of gout,” Badrul Chowdhury, MD, of the FDA’s Center for Drug Evaluation and Research, said in a statement. “[Lesinurad] provides a new treatment option for the millions of people who may develop gout over their lifetimes.”

The drug helps kidneys excrete uric acid by inhibiting the function of transporter proteins involved in uric acid reabsorption in the kidneys. Lesinurad, sold under the brand name Zurampic, was approved for use in combination with a xanthine oxidase inhibitor (XOI), another type of drug used to reduce uric acid production in the body.

First Page Preview View Large
First page PDF preview
First page PDF preview
×